Identification of Combinatorial Genomic Abnormalities Associated with Prostate Cancer Early Recurrence.

[1]  M. Cooperberg,et al.  Overdetection of Recurrence after Radical Prostatectomy: Estimates Based on Patient and Tumor Characteristics , 2014, Clinical Cancer Research.

[2]  J. Stanford,et al.  MP79-08 PTEN LOSS IN LOCALIZED PROSTATE CANCER: CLINICOPATHOLOGIC PARAMETERS AND RELATIONSHIP WITH DISEASE OUTCOME , 2014 .

[3]  P. Nelson,et al.  A Three-Marker FISH Panel Detects More Genetic Aberrations of AR, PTEN and TMPRSS2/ERG in Castration-Resistant or Metastatic Prostate Cancers than in Primary Prostate Tumors , 2013, PloS one.

[4]  J. Cuzick,et al.  Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer , 2013, British Journal of Cancer.

[5]  Arul M Chinnaiyan,et al.  Advancing precision medicine for prostate cancer through genomics. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  J. Hicks,et al.  Assessing the order of critical alterations in prostate cancer development and progression by IHC: further evidence that PTEN loss occurs subsequent to ERG gene fusion , 2013, Prostate Cancer and Prostatic Diseases.

[7]  A. Evans,et al.  PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade , 2013, Modern Pathology.

[8]  J. Hicks,et al.  Cytoplasmic PTEN Protein Loss Distinguishes Intraductal Carcinoma of the Prostate from High Grade Prostatic Intraepithelial Neoplasia , 2012, Modern Pathology.

[9]  C. Plass,et al.  Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. , 2012, The American journal of pathology.

[10]  Jianfeng Xu,et al.  PTEN Protein Loss by Immunostaining: Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer Patients , 2011, Clinical Cancer Research.

[11]  W. Gerald,et al.  Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer , 2010, British Journal of Cancer.

[12]  M. Rubin,et al.  Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort , 2009, Modern Pathology.

[13]  W. Gerald,et al.  TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. , 2009, Cancer research.

[14]  J Cuzick,et al.  Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer , 2008, Oncogene.

[15]  J. Squire,et al.  FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome , 2007, British Journal of Cancer.

[16]  F. Guadagni,et al.  Cytogenetic profiles as additional markers to pathological features in clinically localized prostate carcinoma. , 2006, Cancer letters.

[17]  A. Erbersdobler,et al.  Gain of androgen receptor gene copies in primary prostate cancer due to X chromosome polysomy , 2004, The Prostate.

[18]  P. Nelson,et al.  A novel four-color fluorescence in situ hybridization assay for the detection of TMPRSS2 and ERG rearrangements in prostate cancer. , 2013, Cancer genetics.

[19]  D. Berney,et al.  Duplication of the fusion of TMPRSS 2 to ERG sequences identifies fatal human prostate cancer , 2009 .